ReviewPsychological medicine2021
Translating the promise of 5HT
Review in Psychological medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 46 citations in OpenAlex.
- Mosapride promotes internalization of a TREK1-HTR4 complex and exerts rapid antidepressant-like effects.Molecular psychiatry · 2026Article
- Early effects of a novel 5-HTThe British journal of psychiatry : the journal of mental science · 2026Article
- Serotonin and working memory in mood disorder and healthy states: multi-cohort positron emission tomography study.BJPsych open · 2026Article
- Serotonin receptor 4 in the ventral CA3 regulates agomelatine-induced anxiolytic-like behaviors.Acta pharmacologica Sinica · 2026Article
- Mapping Resting-State Brain Functional Specialization to Neurotransmitter Profiles in Autism Spectrum Disorder.CNS neuroscience & therapeutics · 2025Article
- Prostaglandin FThe Journal of veterinary medical science · 2025Article
- Combinatorial targeting of NMDARs and 5-HTAlzheimer's research & therapy · 2025Article
- Chronic, combinatorial targeting of NMDARs and 5-HTNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2025Article
- Xiao-Chai-Hu-Tang Ameliorates Depressive Symptoms via Modulating Neuro-Endocrine Network in Chronic Unpredictable Mild Stress-Induced Mice.CNS neuroscience & therapeutics · 2025Article
- Pharmaceutical Studies on Piperazine-based Compounds Targeting Serotonin Receptors and Serotonin Reuptake Transporters.Mini reviews in medicinal chemistry · 2025Review
- Sex hormones and serotonin 4 receptor brain binding in men with and without major depressive disorder.Neuroscience applied · 2025Article
- Synaptic Interactions Between Serotonergic and Dopaminergic Systems in Parkinson's Disease.Current neuropharmacology · 2025Review
- Effects of chronic stress on cognitive function - From neurobiology to intervention.Neurobiology of stress · 2024Review
- Effects of a 5-HTScientific reports · 2024Article
- Fenfluramine increases survival and reduces markers of neurodegeneration in a mouse model of Dravet syndrome.Epilepsia open · 2024Article
- SSRIs in the Treatment of Depression: A Pharmacological CUL-DE-SAC?Current topics in behavioral neurosciences · 2024Review
- No association between serotonin 4 receptor brain binding and personality trait Neuroticism - A positron emission tomography study in depressed patients and healthy individuals.Neuroscience applied · 2024Article
- Functional Dimerization of Serotonin Receptors: Role in Health and Depressive Disorders.International journal of molecular sciences · 2023Review
- Stress Hormone Dynamics Are Coupled to Brain Serotonin 4 Receptor Availability in Unmedicated Patients With Major Depressive Disorder: A NeuroPharm Study.The international journal of neuropsychopharmacology · 2023Article
- Sexual health and serotonin 4 receptor brain binding in unmedicated patients with depression-a NeuroPharm study.Translational psychiatry · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
Animal experimental studies suggest that 5-HT4 receptor activation holds promise as a novel target for the treatment of depression and cognitive impairment. 5-HT4 receptors are post-synaptic receptors that are located in striatal and limbic areas known to be involved in cognition and mood. Consistent with this, 5-HT4 receptor agonists produce rapid antidepressant effects in a number of animal models of depression, and pro-cognitive effects in tasks of learning and memory. These effects are accompanied by molecular changes, such as the increased expression of neuroplasticity-related proteins that are typical of clinically useful antidepressant drugs. Intriguingly, these antidepressant-like effects have a fast onset of their action, raising the possibility that 5-HT4 receptor agonists may be a particularly useful augmentation strategy in the early stages of SSRI treatment. Until recently, the translation of these effects to humans has been challenging. Here, we review the evidence from animal studies that the 5-HT4 receptor is a promising target for the treatment of depression and cognitive disorders, and outline a potential pathway for the efficient and cost-effective translation of these effects into humans and, ultimately, to the clinic.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.